Members Only Content
Subscribe to get full access
Free Preview
The synthetic biology deal provides access to a leading protein-engineering platform and bolsters the company's immune tolerance pipeline.
Upstart Recommendation Report Upstart Presentation Slides
Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]
PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]
